Ikarian Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Ikarian Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.8M	Buy	+300,000	New	+$22.6M	2.56%	10

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Ikarian Capital's IONS Position: Q2 2026 in Review

Ikarian Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 127,038 shares — an estimated $9.56M sold.

Ikarian Capital first reported a position in IONS in Q3 2025 and held it in 3 quarters. The position peaked at $27.2M in Q3 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Ikarian Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ikarian Capital sold 127,038 Ionis Pharmaceuticals shares in Q2 2026, an estimated $9.56M.
Ikarian Capital first reported a position in Ionis Pharmaceuticals in Q3 2025 and held it in 3 quarters.
Ikarian Capital's Ionis Pharmaceuticals position peaked at $27.2M in Q3 2025.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.